


# CLAIMS

1. A heterocyclic compound represented by the formula I:



wherein X represents nitrogen atom or CH; Y represents C<sub>1</sub>-C<sub>6</sub> alkyl; R<sub>1</sub> represents morpholino (which may be substituted with one to four C<sub>1</sub>-C<sub>6</sub> alkyl); and R<sub>2</sub> and R<sub>3</sub> each represent hydrogen atom or C<sub>1</sub>-C<sub>6</sub> alkyl.

2. A compound as claimed in claim 1, wherein X is CH, Y being methyl, R<sub>1</sub> being morpholino, each of R<sub>2</sub> and R<sub>3</sub> being methyl.
3. A compound as claimed in claim 1, wherein the compound of the formula I is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(cis-2,6-dimethylmorpholino)-6-morpholinopyrimidine.
4. A compound as claimed in claim 1, wherein the compound

of the formula I is 2-(2-difluoromethyl-4-methoxybenzimidazol-1-yl)-4-(2,2-dimethylmorpholino)-6-morpholinopyrimidine.

5. An anti-malignant-tumor agent containing at least one compound as claimed in claims 1 to 4 as effective component.

6. A pharmaceutical composition including at least one compound as claimed in claims 1 to 4 as anti-malignant-tumor active component together with pharmaceutically acceptable diluent or carrier.